Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Drug Resistance, Neoplasm
  • Epothilones
  • Taxoids

abstract

  • Ixabepilone (40 mg/m(2) as a 3-hour infusion every 3 weeks) demonstrates promising antitumor activity and an acceptable safety profile in patients with taxane-resistant MBC.

publication date

  • August 10, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.08.9102

PubMed ID

  • 17606975

Additional Document Info

start page

  • 3399

end page

  • 406

volume

  • 25

number

  • 23